Dr. George Poste Joins Board of Directors of Caris Diagnostics and Joins Caris, Ltd. as Senior Technical Advisor
Irving, TX - November 14, 2006: Caris Diagnostics, previously Pathology Partners, today announced that George Poste, D.V.M., Ph.D, F.R.C. Path, F.R.S., has joined its Board of Directors as an outside director. As well, Dr. Poste is serving as Senior Technical Advisor to Caris, Ltd., which owns a controlling stake in Caris Diagnostics.
Dr. Poste is Director of The Biodesign Institute at Arizona State University, an innovative program that combines research in biotechnology, nanotechnology, materials science, advanced computing and neuromorphic engineering. He also serves as Chief Executive of Health Technology Networks, a consulting firm that specializes in the application of genomic technologies and computing in healthcare. From 1992 to 1999, he was Chief Science and Technology Officer and president of Research & Development for SmithKline Beecham, where he oversaw the registration of 31 drug, vaccine and diagnostic products. Dr. Poste is a Board Certified Pathologist, a Fellow of the Royal Society and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution of Stanford University and a member of the Council for Foreign Relations.
“George brings a tremendous perspective as a Board member of Caris Diagnostics. He is active in leading edge research in the healthcare field. As we expand our focus in pathology and look at where it will be ten years from now, versus where it is today, George’s insights will be invaluable. We welcome George and appreciate his contributions to our team,” said David D. Halbert, Chairman of Caris Diagnostics.
Dr. Poste has published over 350 scientific papers and co-edited 14 books on cancer, drug delivery and health policy. He has received honorary degrees in Science and Law for his research contributions and was awarded the rank of Commander of the British Empire by HM Queen Elizabeth II for his services to international health. In 2004 he was named “R&D Scientist of the Year” by R&D Magazine.
“I am honored to join the Caris Diagnostics and Caris, Ltd. teams,” commented Dr. Poste. “This is an area about which I am passionate. I have enjoyed working with David before in high growth situations and am looking forward to doing so once again.”
About Caris Diagnostics
Caris Diagnostics provides superior GI diagnostic services to physicians who treat patients in an ambulatory setting. The company leads the industry in the number of sub-specialty fellowship and expert trained pathologists in gastrointestinal and hepatic pathology. Additionally, Caris Diagnostics provides constant, dependable specimen processing and reporting within 48 hours. Each report includes detailed diagnostic descriptions and color images in an easy-to-read, concise and complete format. More than 1,200 GI physicians nationally use Caris Diagnostics. Formed in 1996, the company is headquartered in Irving, Texas. Additional information is available at www.carisdiagnostics.com, or by calling 214-277-8700.
About Caris, Ltd.
Caris, Ltd. is a privately held investment partnership, with approximately $350 million of assets under management. Caris makes long-term, strategic investments principally in the private marketplace. Targeted sectors for Caris include health care, energy and financial services. Caris brings a successful track record of building sustainable business enterprises and partnering with management teams. Further information on the company is available at www.carisltd.com, or by calling 972-590-2100.